ENTITY
Keymed Biosciences

Keymed Biosciences (2162 HK)

65
Analysis
Health CareHong Kong
Keymed Biosciences Inc. operates a biotechnology company. The Company focus on the in-house discovery and development of innovative biological therapies. Keymed Biosciences provides services in China.
more
Refresh
16 Sep 2021 10:00

HSCI Index Rebalance and Stock Connect: Potential Changes in December and March

There could be 5 adds to the HSCI in December. In March, there could be 17 adds and 4 deletes. There will be pre-positioning on the inclusions...

Logo
463 Views
Share
22 Jul 2021 09:09

Pre-IPO Transcenta Holding - Insights on Pipeline and the Concerns

The article mainly analyzed Transcenta Holding in terms of its important product candidates MSB2311, TST001, TST005 and MSB0254,including the...

Logo
233 Views
Share
07 Jul 2021 11:14

Keymed (康诺亚生物) IPO Trading: CDE Consultation Paper Marginally Positive for Pipeline

We look at the updates of Keymed IPO since our last note. Sentiments were positive for the deal as we have expected. The recent CDE consultation...

Logo
246 Views
Share
04 Jul 2021 10:21

ECM Weekly (4th July 2021) - Xpeng, Medbot, Medlive, Brii Bio, CTOS, LinkDoc, Devyani, Manycore

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Share
bearish3SBio Inc
29 Jun 2021 09:09

3SBio Inc (1530.HK) - The Concerns and the Outlook

This insight mainly analyzed the potential reasons behind the decline in 3SBio Group's share price, the important products, the pipeline, the...

Logo
238 Views
Share
x